Replimune Group Inc (NASDAQ:REPL) Stock Holdings Boosted by Wells Fargo & Company MN

Wells Fargo & Company MN lifted its position in shares of Replimune Group Inc (NASDAQ:REPL) by 211.3% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 23,090 shares of the company’s stock after acquiring an additional 15,672 shares during the period. Wells Fargo & Company MN owned 0.07% of Replimune Group worth $338,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently added to or reduced their stakes in the company. Redmile Group LLC grew its position in shares of Replimune Group by 1.1% during the first quarter. Redmile Group LLC now owns 2,212,456 shares of the company’s stock worth $33,674,000 after acquiring an additional 23,499 shares during the last quarter. Emerald Mutual Fund Advisers Trust grew its position in shares of Replimune Group by 0.5% during the second quarter. Emerald Mutual Fund Advisers Trust now owns 711,770 shares of the company’s stock worth $10,435,000 after acquiring an additional 3,650 shares during the last quarter. Rhumbline Advisers bought a new position in shares of Replimune Group during the first quarter worth about $174,000. Finally, BNP Paribas Arbitrage SA bought a new position in shares of Replimune Group during the first quarter worth about $38,000. Institutional investors and hedge funds own 60.74% of the company’s stock.

In related news, CEO Robert Coffin sold 24,250 shares of the company’s stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $17.05, for a total value of $413,462.50. Also, Chairman Philip Astley-Sparke sold 14,500 shares of the company’s stock in a transaction dated Monday, September 23rd. The stock was sold at an average price of $17.05, for a total transaction of $247,225.00. Insiders sold 50,000 shares of company stock valued at $852,500 in the last ninety days. Corporate insiders own 63.18% of the company’s stock.

REPL stock opened at $11.61 on Wednesday. The company has a market capitalization of $402.79 million, a P/E ratio of -8.73 and a beta of 3.23. The company has a 50-day simple moving average of $12.13 and a 200 day simple moving average of $13.44. Replimune Group Inc has a fifty-two week low of $8.88 and a fifty-two week high of $18.25.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.02. On average, sell-side analysts expect that Replimune Group Inc will post -1.52 EPS for the current fiscal year.

Several equities analysts have recently commented on REPL shares. Zacks Investment Research lowered shares of Replimune Group from a “buy” rating to a “hold” rating in a research report on Tuesday, August 20th. Chardan Capital reaffirmed a “buy” rating and issued a $28.00 price objective on shares of Replimune Group in a report on Thursday, August 15th. JPMorgan Chase & Co. raised shares of Replimune Group from a “neutral” rating to an “overweight” rating and reduced their price objective for the stock from $27.00 to $26.00 in a report on Friday, July 12th. Roth Capital started coverage on shares of Replimune Group in a report on Wednesday, September 4th. They issued a “buy” rating and a $20.00 price objective for the company. Finally, ValuEngine downgraded shares of Replimune Group from a “buy” rating to a “hold” rating in a report on Friday, September 20th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $23.33.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors.

Recommended Story: What is cost of equity?

Institutional Ownership by Quarter for Replimune Group (NASDAQ:REPL)

Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.